Strong Q2 (May-July) and encouraging trading statement for August.

Another setback in R&D could change the market's perception on Novartis.

Feud at the top continues.

Lackluster results with poor Gameloft performance - cautious stance reiterated.

Another key contract gained with PepsiCo.

Disposal of the mainstream vitamin/ minerals business.